公开(公告)号：US12129294B2

公开(公告)日：2024-10-29

申请号：US18105316

申请日：2023-02-03

Applicant: AbbVie Inc.

Inventor： Gregg Timony ,  Sheila Gujrathi ,  Robert Peach ,  Allan Olson

IPC: C07K16/24 ,  A61K31/436 ,  A61K31/519 ,  A61K31/58 ,  A61K38/13 ,  A61K39/395 ,  A61K45/06 ,  A61P1/00 ,  A61P37/06

CPC classification number: C07K16/244 ,  A61K31/436 ,  A61K31/519 ,  A61K31/58 ,  A61K38/13 ,  A61K39/3955 ,  A61K45/06 ,  A61P1/00 ,  A61P37/06 ,  C07K2317/56

Abstract: The present invention is directed to methods for treating diseases in which IL-13 activity is detrimental, including eosinophilic esophagitis (EoE) and asthma, by administering to a subject in need of such treatment, a composition containing an interleukin-13 (IL-13) antibody, or an antigen binding fragment, thereof.

公开(公告)号：US20240335644A1

公开(公告)日：2024-10-10

申请号：US18403636

申请日：2024-01-03

Applicant: BIORA THERAPEUTICS, INC.

Inventor： Mitchell Lawrence Jones ,  Sharat Singh ,  Christopher Loren Wahl ,  Harry Stylli

IPC: A61M31/00 ,  A61B5/00 ,  A61K9/00 ,  A61K9/48 ,  A61K31/436 ,  A61K38/13 ,  A61P1/04 ,  C07K16/24 ,  C07K16/28 ,  C12N15/113

CPC classification number: A61M31/002 ,  A61B5/6873 ,  A61K9/0009 ,  A61K9/0019 ,  A61K9/0053 ,  A61K9/48 ,  A61K31/436 ,  A61K38/13 ,  A61P1/04 ,  C07K16/241 ,  C07K16/244 ,  C07K16/2839 ,  C12N15/113 ,  A61B5/0059

Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with an immune modulatory agent (e.g., a CD40/CD40L inhibitor).

公开(公告)号：US12109302B2

公开(公告)日：2024-10-08

申请号：US18227463

申请日：2023-07-28

Applicant: Ocular Therapeutix, Inc.

Inventor： Charles D. Blizzard ,  Rami El-Hayek ,  Michael Goldstein ,  Peter Jarrett ,  Andrew Vanslette

IPC: A61K9/00 ,  A61K38/13 ,  A61K47/10 ,  A61K47/22 ,  A61P27/02

CPC classification number: A61K9/0051 ,  A61K38/13 ,  A61K47/10 ,  A61K47/22 ,  A61P27/02

Abstract: Provided herein are sustained release biodegradable intracanalicular insert comprising a hydrogel and cyclosporine, methods of treating or preventing an ocular disease in a subject in need thereof by administering such inserts as well as methods of manufacturing such inserts.

公开(公告)号：US20240307294A1

公开(公告)日：2024-09-19

申请号：US18664525

申请日：2024-05-15

Applicant: EMOLLIVET AB

Inventor： Bengt Herslöf ,  Jan Holmbäck

IPC: A61K9/00 ,  A61K8/34 ,  A61K8/36 ,  A61K8/365 ,  A61K8/368 ,  A61K8/42 ,  A61K8/49 ,  A61K8/55 ,  A61K9/06 ,  A61K9/12 ,  A61K31/137 ,  A61K31/167 ,  A61K31/192 ,  A61K31/196 ,  A61K31/197 ,  A61K31/455 ,  A61K31/573 ,  A61K31/575 ,  A61K31/60 ,  A61K31/7056 ,  A61K38/13 ,  A61K38/16 ,  A61K47/10 ,  A61K47/12 ,  A61K47/18 ,  A61K47/22 ,  A61K47/24 ,  A61Q15/00 ,  A61Q19/00

CPC classification number: A61K9/0014 ,  A61K8/34 ,  A61K8/361 ,  A61K8/365 ,  A61K8/368 ,  A61K8/42 ,  A61K8/494 ,  A61K8/4946 ,  A61K8/553 ,  A61K31/137 ,  A61K31/167 ,  A61K31/192 ,  A61K31/196 ,  A61K31/197 ,  A61K31/455 ,  A61K31/573 ,  A61K31/575 ,  A61K31/60 ,  A61K31/7056 ,  A61K38/13 ,  A61K38/16 ,  A61K47/10 ,  A61K47/12 ,  A61K47/18 ,  A61K47/22 ,  A61K47/24 ,  A61Q19/00 ,  A61K9/06 ,  A61K9/12 ,  A61Q15/00

Abstract: The present invention provides topical pharmaceutical or cosmetic compositions comprising a pharmaceutical or cosmetic carrier comprising at least 3% by weight of phospholipid; at least 20% by weight of C2-C4 alcohol;at least 0.05% by weight keratolytic agent; and optionally, comprising up to 2% by weight of water; and pharmacologically or cosmetically active agent dissolved in said carrier. The compositions are sprayable. Also disclosed is a method of preparing the composition and use thereof, as well as the pharmaceutical or cosmetic carriers as such.

公开(公告)号：US12083185B2

公开(公告)日：2024-09-10

申请号：US17284562

申请日：2019-10-11

Applicant: University of Pittsburgh—Of the Commonwealth System of Higher Education

Inventor： Jingjing Sun ,  Song Li

IPC: A61K47/69 ,  A61K9/107 ,  A61K31/12 ,  A61K31/138 ,  A61K31/337 ,  A61K31/366 ,  A61K31/404 ,  A61K31/405 ,  A61K31/436 ,  A61K31/506 ,  A61K31/551 ,  A61K31/7068 ,  A61K38/13 ,  A61K47/54 ,  A61K47/58 ,  A61K47/60

CPC classification number: A61K47/6907 ,  A61K9/1075 ,  A61K31/12 ,  A61K31/138 ,  A61K31/337 ,  A61K31/366 ,  A61K31/404 ,  A61K31/405 ,  A61K31/436 ,  A61K31/506 ,  A61K31/551 ,  A61K31/7068 ,  A61K38/13 ,  A61K47/54 ,  A61K47/542 ,  A61K47/58 ,  A61K47/60

Abstract: A polymer includes a hydrophobic polymer backbone, a first plurality of pendant groups attached to the hydrophobic polymer backbone and including at least one group including a plurality of hydroxyl groups, and a second plurality of pendant groups attached to the hydrophobic polymer backbone and comprising at least one hydrophilic polymer.

公开(公告)号：US12083122B2

公开(公告)日：2024-09-10

申请号：US18216089

申请日：2023-06-29

Applicant: ARCUTIS BIOTHERAPEUTICS, INC.

Inventor： David W. Osborne

IPC: A61K31/519 ,  A61K9/00 ,  A61K9/08 ,  A61K31/5377 ,  A61K31/573 ,  A61K38/13 ,  A61K47/10 ,  A61K47/20

CPC classification number: A61K31/519 ,  A61K9/0014 ,  A61K9/08 ,  A61K31/5377 ,  A61K31/573 ,  A61K38/13 ,  A61K47/10 ,  A61K47/20

Abstract: The present invention is a method and composition comprising laureth-4 in topical formulations, wherein the laureth-4 increases the penetration of active ingredients across the skin. In a particularly preferred embodiment, the active ingredient is SHR0302.

公开(公告)号：US20240293408A1

公开(公告)日：2024-09-05

申请号：US18372398

申请日：2023-09-25

Applicant: Pharmacyclics LLC

Inventor： John C. BYRD ,  Jason A. Dubovsky ,  Natarajan Muthusamy ,  Amy J. Johnson ,  David Miklos

IPC: A61K31/519 ,  A61K31/5377 ,  A61K31/56 ,  A61K35/17 ,  A61K35/28 ,  A61K38/13 ,  A61K45/06 ,  A61P35/00 ,  A61P35/02 ,  A61P43/00

CPC classification number: A61K31/519 ,  A61K31/5377 ,  A61K31/56 ,  A61K35/17 ,  A61K38/13 ,  A61K45/06 ,  A61P35/00 ,  A61P35/02 ,  A61P43/00 ,  A61K35/28

Abstract: Described herein are methods for treating and preventing graft versus host disease using ACK inhibitors. The methods include administering to an individual in need thereof an ACK inhibitor such as ibrutinib for treating and preventing graft versus host disease.

公开(公告)号：US20240252319A1

公开(公告)日：2024-08-01

申请号：US18436364

申请日：2024-02-08

Applicant: CorMatrix Cardiovascular, Inc.

Inventor： Robert G. Matheny

IPC: A61F2/24 ,  A61K31/366 ,  A61K31/40 ,  A61K31/405 ,  A61K31/436 ,  A61K31/44 ,  A61K31/57 ,  A61K31/573 ,  A61K38/13 ,  A61L27/24 ,  A61L27/36 ,  A61L27/54

CPC classification number: A61F2/2475 ,  A61K31/366 ,  A61K31/40 ,  A61K31/405 ,  A61K31/436 ,  A61K31/44 ,  A61K31/57 ,  A61K31/573 ,  A61K38/13 ,  A61L27/24 ,  A61L27/3625 ,  A61L27/54 ,  A61L2300/204 ,  A61L2300/216 ,  A61L2300/252 ,  A61L2300/434 ,  A61L2430/20

Abstract: A conical shaped venous valve structure with a plurality of fluid flow modulating means that open and allow antegrade blood to be transmitted out of the valve structure and into and through an associated cardiovascular vessel when the valve structure is disposed in the cardiovascular vessel and the antegrade blood exhibits a positive pressure relative to the exterior pressure.

公开(公告)号：US20240218330A1

公开(公告)日：2024-07-04

申请号：US18288768

申请日：2022-04-26

Applicant: Ospedale San Raffaele S.r.l. ,  Fondazione Telethon

Inventor： Anna Christina Kajaste-Rudnitski ,  Erika Valeri ,  Giulia Unali ,  Francesco Piras

IPC: C12N5/0789 ,  A61K31/513 ,  A61K31/7072 ,  A61K35/28 ,  A61K38/13 ,  C12N15/86

CPC classification number: C12N5/0647 ,  A61K31/513 ,  A61K31/7072 ,  A61K35/28 ,  A61K38/13 ,  C12N15/86 ,  C12N2500/40 ,  C12N2501/04 ,  C12N2510/00 ,  C12N2740/15043

Abstract: A combination of: (a) at least one deoxyribonucleoside (dN) or a derivative thereof and cyclosporin H (CsH) or a derivative thereof: or (b) at least one pyrimidine precursor and cyclosporin H (CsH) or a derivative thereof.

公开(公告)号：US20240197818A1

公开(公告)日：2024-06-20

申请号：US18590539

申请日：2024-02-28

Applicant: SUN PHARMACEUTICAL INDUSTRIES LIMITED

Inventor： Sidney L. WEISS ,  Ashim K. MITRA ,  Eugene J. MCNALLY

IPC: A61K38/13 ,  A61K9/00 ,  A61K9/107 ,  A61K31/202 ,  A61K47/10 ,  A61K47/44 ,  A61P27/02

CPC classification number: A61K38/13 ,  A61K9/0048 ,  A61K9/107 ,  A61K31/202 ,  A61K47/10 ,  A61K47/44 ,  A61P27/02

Abstract: Provided herein are formulations for topical ophthalmic formulations containing 0.087-0.093 wt % of cyclosporine, and methods of making and using such formulations. In some aspects and embodiments the formulations may include a polyoxyl lipid or fatty acid, and/or a polyalkoxylated alcohol and may include nanomicelles. Also included herein are methods of treating or preventing diseases or conditions, such as ocular diseases or conditions.